Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaker A Mousa

Showing results (91-100 of 435) with videos related to

Pageof 44
Sort By:
Vascular Health and Risk Management|June 20, 2008
Preferred drug lists: potential impact on healthcare economicsKimberly Ovsag, Sabrina Hydery, Shaker A Mousa
Current Medicinal Chemistry|June 29, 2019
Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in CancerMehdi Rajabi, Mary Adeyeye, Shaker A Mousa
Advances in Nutrition (Bethesda, Md.)|February 15, 2012
Omega-3 fatty acids EPA and DHA: health benefits throughout lifeDanielle Swanson, Robert Block, Shaker A Mousa
Cardiovascular Drug Reviews|April 15, 2006
Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?Shaker A Mousa, Hikmat N Abdel-Razeq
Cancers|July 2, 2021
Anti-Cancer Activities of Thyrointegrin α<sub>v</sub>β<sub>3</sub> Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in GlioblastomaKavitha Godugu, Mehdi Rajabi, Shaker A Mousa
Expert Opinion on Biological Therapy|May 5, 2007
Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failureShaker A Mousa, Olga Goncharuk, Danny Miller
Bioorganic & Medicinal Chemistry Letters|March 10, 2018
Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancerMehdi Rajabi, Murat Yalcin, Shaker A Mousa
Current Opinion in Investigational Drugs (London, England : 2000)|September 28, 2010
Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applicationsAhmad Aljada, Lynn Dong, Shaker A Mousa
Current Opinion in Investigational Drugs (London, England : 2000)|July 26, 2002
Antithrombotics and thrombolytics in strokeShaker A Mousa, Omar Iqbal, Jawed Fareed
Journal of Clinical Pharmacology|July 15, 2003
Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjectsShaker A Mousa, Jeffrey Bozarth, Jeffrey S Barrett
Pageof 44

Showing results (91-100 of 435) with videos related to

Sort By:
Pageof 44
Vascular Health and Risk Management|June 20, 2008
Preferred drug lists: potential impact on healthcare economicsKimberly Ovsag, Sabrina Hydery, Shaker A Mousa
Current Medicinal Chemistry|June 29, 2019
Peptide-Conjugated Nanoparticles as Targeted Anti-angiogenesis Therapeutic and Diagnostic in CancerMehdi Rajabi, Mary Adeyeye, Shaker A Mousa
Advances in Nutrition (Bethesda, Md.)|February 15, 2012
Omega-3 fatty acids EPA and DHA: health benefits throughout lifeDanielle Swanson, Robert Block, Shaker A Mousa
Cardiovascular Drug Reviews|April 15, 2006
Ximelagatran, the new oral anticoagulant: would warfarin survive the challenge?Shaker A Mousa, Hikmat N Abdel-Razeq
Cancers|July 2, 2021
Anti-Cancer Activities of Thyrointegrin α<sub>v</sub>β<sub>3</sub> Antagonist Mono- and Bis-Triazole Tetraiodothyroacetic Acid Conjugated via Polyethylene Glycols in GlioblastomaKavitha Godugu, Mehdi Rajabi, Shaker A Mousa
Expert Opinion on Biological Therapy|May 5, 2007
Recent advances of TNF-alpha antagonists in rheumatoid arthritis and chronic heart failureShaker A Mousa, Olga Goncharuk, Danny Miller
Bioorganic & Medicinal Chemistry Letters|March 10, 2018
Synthesis of new analogs of tetraiodothyroacetic acid (tetrac) as novel angiogenesis inhibitors for treatment of cancerMehdi Rajabi, Murat Yalcin, Shaker A Mousa
Current Opinion in Investigational Drugs (London, England : 2000)|September 28, 2010
Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applicationsAhmad Aljada, Lynn Dong, Shaker A Mousa
Current Opinion in Investigational Drugs (London, England : 2000)|July 26, 2002
Antithrombotics and thrombolytics in strokeShaker A Mousa, Omar Iqbal, Jawed Fareed
Journal of Clinical Pharmacology|July 15, 2003
Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjectsShaker A Mousa, Jeffrey Bozarth, Jeffrey S Barrett
Pageof 44